- Home
- NEGG vs CHRS Comparison
NEGG vs CHRS Comparison
Compare NEGG & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- CHRS
- Stock Information
- Founded
- NEGG 2001
- CHRS 2010
- Country
- NEGG United States
- CHRS United States
- Employees
- NEGG 932
- CHRS 235
- Industry
- NEGG Other Specialty Stores
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEGG Consumer Discretionary
- CHRS Health Care
- Exchange
- NEGG Nasdaq
- CHRS Nasdaq
- Market Cap
- NEGG 171.3M
- CHRS 134.4M
- IPO Year
- NEGG 2010
- CHRS 2014
- Fundamental
- Price
- NEGG $0.44
- CHRS $1.16
- Analyst Decision
- NEGG
- CHRS Strong Buy
- Analyst Count
- NEGG 0
- CHRS 4
- Target Price
- NEGG N/A
- CHRS $5.38
- AVG Volume (30 Days)
- NEGG 1.1M
- CHRS 2.4M
- Earning Date
- NEGG 08-29-2024
- CHRS 03-12-2025
- Dividend Yield
- NEGG N/A
- CHRS N/A
- EPS Growth
- NEGG N/A
- CHRS N/A
- EPS
- NEGG N/A
- CHRS N/A
- Revenue
- NEGG $1,391,833,000.00
- CHRS $304,340,000.00
- Revenue This Year
- NEGG $6.01
- CHRS $2.47
- Revenue Next Year
- NEGG N/A
- CHRS N/A
- P/E Ratio
- NEGG N/A
- CHRS N/A
- Revenue Growth
- NEGG N/A
- CHRS 44.19
- 52 Week Low
- NEGG $0.39
- CHRS $0.66
- 52 Week High
- NEGG $1.32
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- NEGG 43.37
- CHRS 38.01
- Support Level
- NEGG $0.39
- CHRS $1.03
- Resistance Level
- NEGG $0.49
- CHRS $1.39
- Average True Range (ATR)
- NEGG 0.04
- CHRS 0.14
- MACD
- NEGG 0.00
- CHRS -0.03
- Stochastic Oscillator
- NEGG 26.45
- CHRS 14.04
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.